Transjugular intrahepatic portal-systemic shunting
|
|
- Lynn Cook
- 5 years ago
- Views:
Transcription
1 Quality of Life in Refractory Ascites: Transjugular Intrahepatic Portal-Systemic Shunting Versus Medical Therapy Mical S. Campbell, 1 Colleen M. Brensinger, 2 Arun J. Sanyal, 3 Chris Gennings, 4 Florence Wong, 5 Kris V. Kowdley, 6 Timothy McCashland, 7 and K. Rajender Reddy 1 Uncontrolled studies suggest that transjugular intrahepatic portal-systemic shunting (TIPS) may improve quality of life in patients with refractory ascites. We hypothesized that any improvement of quality of life in patients with TIPS would be matched in controls due to the competing effects of improved ascites and worsened hepatic encephalopathy. Thus, an analysis of quality of life was performed using original data from the North American Study for the Treatment of Refractory Ascites, a multicenter trial of 109 patients randomized to TIPS or repeated large volume paracentesis (LVP) for refractory ascites. Short form 36 (SF-36) surveys were completed at baseline and at 6- and 12-month follow-up. Variables analyzed were: randomization group, number of LVP performed, cumulative volume from LVP, shortness of breath, abdominal distention, abdominal pain, diuretic usage, confusion, hospitalizations, and emergency room visits. Outcomes were changes in physical component scale (PCS) and mental component scale (MCS) of SF-36 results. We constructed multivariable, mixed effects models, including randomization group and baseline MCS and PCS. Changes in PCS and MCS from baseline were similar between the two randomization groups. In multivariate analysis, PCS improvement was associated with lack of confusion, improved ascites, and lack of hospitalizations, but not directly with randomization group. Improvement in MCS was associated with randomization to TIPS and lack of confusion. In conclusion, patients with refractory ascites randomized to TIPS or repeated LVP had similar changes in quality of life. Competing effects of hepatic encephalopathy, requirement for repeated LVP, and need for hospitalizations explain similar changes in quality of life between the two groups. (HEPATOLOGY 2005;42: ) Abbreviations: TIPS, transjugular intrahepatic portal-systemic shunting; LVP, large volume paracentesis; SF-36, short form 36; PCS, physical component scale; MCS, mental component scale. From the 1 Division of Gastroenterology, University of Pennsylvania Health Services, 2 Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA; 3 Department of Internal Medicine and 4 Department of Biostatistics, Virginia Commonwealth University, Richmond, VA; 5 Department of Medicine, University of Toronto, Toronto, Ontario, Canada; 6 Department of Internal Medicine, University of Washington, Seattle, WA; 7 Department of Internal Medicine, University of Nebraska, Omaha, NE. Received March 30, 2005; accepted June 21, Supported by Grant R01 DK from the National Institutes of Health (to A.J.S.) and Grant M01-RR Address reprint requests to: K. Rajender Reddy, M.D., Division of Gastroenterology, 3 Ravdin, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA rajender.reddy@uphs.upenn.edu; fax: (215) Copyright 2005 by the American Association for the Study of Liver Diseases. Published online in Wiley InterScience ( DOI /hep Potential conflict of interest: Nothing to report. Transjugular intrahepatic portal-systemic shunting (TIPS) is increasingly used for the treatment of refractory ascites. Most randomized trials have not demonstrated a survival advantage for TIPS over medical therapy. 1-5 Therefore, any advantage that TIPS might have in this setting would lie in differences of cost and quality of life. Features which have been associated with poorer quality of life in patients with advanced liver disease include: ascites, requirement for hospitalizations, number and types of medications, Child-Turcotte-Pugh class, hepatic encephalopathy, muscle cramps, and pruritus. 6-9 Quality of life is likely not affected by gender, race, and etiology of liver disease. 6-9 Conflicting data on the association between age and quality of life have been reported. 6-8 TIPS performed for the treatment of refractory ascites might be expected to improve quality of life. A successful TIPS may eliminate or minimize the requirement for diuretics and the need to undergo repeated large volume 635
2 636 CAMPBELL ET AL. HEPATOLOGY, September 2005 paracenteses (LVP). Patients might experience less shortness of breath, early satiety, and gastrointestinal bleeding, as well as fewer emergency department visits. In fact, limited, uncontrolled experience has suggested improved quality of life after performing TIPS for ascites On the other hand, some patients may suffer deterioration in their quality of life due to hepatic encephalopathy, diarrhea and discomfort from lactulose, and repeated testing to ensure TIPS patency, including invasive venography procedures. Furthermore, TIPS may fail to resolve ascites in up to one half of cases. 1-5 The present study was performed to determine differences in quality of life between patients undergoing TIPS versus repeated LVP for the treatment of refractory ascites. Clinical variables were correlated with changes in quality of life. Patients and Methods A secondary analysis was performed of original patient data from the North American Study for Treatment of Refractory Ascites, an international, multicenter, prospective, randomized controlled trial. 1 The study included 109 subjects with refractory ascites, stringently defined according to International Ascites Club criteria. 13 Removal of at least 10 L of ascites in the preceding 2 months for symptom relief was required for entry into the study. Furthermore, patients had either failed to respond to a maximum of 160 mg/d of furosemide and 400 mg/d of spironolactone (or equivalent doses of loop-acting and distal-acting diuretics), or they could not tolerate highdose diuretics because of hyponatremia, hyperkalemia, azotemia, or encephalopathy. All patients were on dietary sodium restriction between 50 and 66 meq/d. Patients included in the study had serum creatinine levels of less than 1.5 mg/dl for at least 7 days before study entry, as well as total bilirubin levels of less than 5 mg/dl and an international normalized ratio of less than 2. Subjects were randomized to either repeated LVP and intravenous albumin infusion (n 57) or to TIPS (n 52). Patients randomized to the TIPS arm underwent LVP at the time of TIPS. All subjects remained on a sodium-restricted diet and diuretics. LVP was performed as necessary during study follow-up for recurrence of tense, symptomatic ascites in patients with a weight gain of more than 10 lbs. (4.5 kg) from immediately previous nadir weight despite maximal diuretic therapy, or if patients had recurrence and were unable to use an effective dose of diuretics as a result of diuretic-related side effects. TIPS was placed successfully in 49 patients (94%). Assisted stent patency at 1 year was more than 90% in surviving subjects. Extensive and carefully documented clinical, laboratory, and radiological data were collected during the course of the study. Over the course of 1 year patients had at least 10 follow-up visits per protocol. At each visit, investigators assessed whether subjects had experienced the following interval symptoms: shortness of breath, abdominal distention, abdominal pain, and confusion. Other variables assessed during follow-up were visits to the emergency department, hospitalizations, requirement for LVP, number of LVP performed, quantity of ascites fluid removed, TIPS thrombosis, gastrointestinal bleeding, requirement for lactulose, and diuretic dosage. Clinical outcomes were reported for the first and second 6 months of follow-up. If a patient was symptomatic during at least one visit, that patient was counted as having experienced the symptom during the corresponding 6-month period. Diuretic dosage at the end of each 6-month period was reported. Dosages were considered low if patients were taking no more than 40 mg/d furosemide or 100 mg/d of spironolactone (or up to 1 mg/d bumetanide and 5 mg/d amiloride). Dosages were considered high if patients were taking 120 mg/d or more of furosemide or 300 mg/d or more of spironolactone (or 3 mg/d or more of bumetanide or 15 mg/d or more of amiloride). Patients were censored from the study at the time of death or liver transplantation. Short form 36 (SF-36) questionnaires were administered to all patients at baseline randomization and at 6- and 12-month follow-up. The SF-36 is a general quality of life assessment with 36 questions divided into eight scales: (1) physical function, (2) physical role limitation, (3) bodily pain, (4) general health, (5) vitality, (6) social functioning, (7) emotional role limitation, and (8) mental health. Two standardized indices, the physical component scale (PCS) and the mental component scale (MCS), can be calculated from SF-36 raw data. 14 Ranges for the MCS and PCS are 8 to 73 and 10 to 74, respectively. The SF-36 is widely used and has been validated in diverse disease states. 14 It has also proven useful for the evaluation of quality of life in patients with advanced liver disease. 6,7,15,16 In fact, the SF-36 is a standard to which new liver disease quality of life assessments are compared. 16 Statistical Analysis. Parametric variables were reported as means and standard deviations, and nonnormally distributed variables were reported as quartiles and ranges. Tests for equality of proportions were used for comparing dichotomous variables between randomization groups. Mixed effects models, including baseline PCS or MCS score, assessed the association between clinical variables and change in mean PCS or MCS, looking for effect modification by time of follow-up (6- or 12- month). Multivariable mixed effects models were generated via stepwise backward elimination, using a P value greater than.05 to remove variables not significantly as-
3 HEPATOLOGY, Vol. 42, No. 3, 2005 CAMPBELL ET AL. 637 sociated with outcome. All univariate variables with P values less than.20 were considered for multivariate analyses. A randomization group was also included in each multivariate model. Baseline characteristics (age, sex, race, and cause of liver disease) were similar between the two randomization groups. 1 Statistical programs used were SAS 8.2 (SAS Institute, Cary, NC) and Stata 8.1 (Stata Corporation, College Station, TX). A P value of less than.05 was considered significant. Results One hundred six (97%) patients completed the baseline SF-36 survey. At 6-month follow-up, 56 of 64 patients (88%) completed a follow-up SF-36, and 51 of 54 patients (93%) were surveyed at 12 months (Fig. 1). Reasons for failure to complete the survey were not obtained. Fifty-four subjects exited the study at various time ponts (26 deaths, 27 liver transplantations, and 1 voluntary withdrawal). Baseline and follow-up survey data were available for a similar proportion of patients in the TIPS and LVP groups (P.27). Clinical characteristics differed between TIPS and LVP groups during follow-up (Table 1). Patients randomized to TIPS required fewer LVP with less cumulative ascites fluid removal. TIPS patients also required Fig. 1. Patient flow diagram. QOL, quality of life; TIPS, transjugular intrahepatic portal-systemic shunt group; LVP, large volume paracentesis group lower diuretic dosages. Furthermore, TIPS patients had lower rates of shortness of breath and abdominal distention, but higher rates of confusion and hospitalizations. Age, sex, race, and cause of liver disease were not associated with statistically significant changes in PCS and MCS. Changes in PCS and MCS during follow-up were not significantly different between the two groups (Table 2), although there may have been a trend toward greater quality of life improvement in MCS after TIPS (P.06). Table 1. Clinical Characteristics of Each Randomization Group During First and Second 6 Months of Follow-up Variable TIPS Group: Number (%) or Median (25%, 75%, range)* LVP Group: Number (%) or Median (25%, 75%, range)* P Value LVP required 0-6 months 10 (27%) 29 (88%) months 2 (7%) 17 (63%).001 Number LVP 0-6 months 0 (0, 1, 0-14) 4 (2, 7, 0-12) months 0 (0, 0, 0-8) 1 (0, 7, 0-16).001 Cumulative ascites (L) 0-6 months 0 (0, 2, 0-116) 17 (9, 52, 0-130) months 0 (0, 0, 0-117) 7 (0, 54, 0-132).001 Shortness of breath 0-6 months 16 (43%) 26 (79%) months 7 (23%) 15 (56%).01 Abdominal distention 0-6 months 31 (84%) 32 (97%) months 9 (30%) 22 (81%).001 Diuretic usage 0-6 months.01 No diuretics 9 (24%) 4 (13%) Low dose 19 (51%) 7 (23%) Moderate dose 5 (14%) 8 (26%) High dose 4 (11%) 12 (39%) 6-12 months.006 No diuretics 5 (19%) 6 (24%) Low dose 13 (48%) 6 (24%) Moderate dose 7 (26%) 7 (28%) High dose 2 (7%) 6 (24%) Abdominal pain 0-6 months 27 (73%) 23 (70%) months 15 (50%) 14 (52%).88 Confusion 0-6 months 18 (49%) 8 (24%) months 9 (30%) 6 (22%).51 Taking lactulose 0-6 months 31 (84%) 24 (73%) months 24 (80%) 17 (65%).22 Hospitalizations 0-6 months 21 (57%) 8 (24%) months 11 (37%) 10 (38%).89 Emergency department visits 0-6 months 15 (41%) 14 (42%) months 9 (30%) 6 (23%).56 Gastrointestinal bleeding 0-6 months 0 (0%) 3 (9%) months 1 (3%) 3 (12%).25 *Only patients with complete follow-up for each time period are considered. Significant at P.05 level.
4 638 CAMPBELL ET AL. HEPATOLOGY, September 2005 Table 2. Changes in PCS and MCS by Treatment Group Group Baseline 6 Months* On univariate analysis, significant predictors of change in PCS were recurrent ascites, severe recurrent ascites (three or more LVP or 15 L cumulative ascites removed), confusion, and shortness of breath. Presence of abdominal distention and requirement for hospitalization were significant predictors only at 12-month follow-up (Table 3). On multivariate analysis, randomization to TIPS group was not a significant predictor of PCS. Severe ascites (three or more LVP), confusion, and need for hospitalizations by the 12-month visit were associated with declines in PCS (Table 4). On univariate analysis, no clinical variable was associated with change in MCS scores (Table 5). On multivariate analysis, TIPS patients had improved quality of life after adjusting for the negative effect of confusion on MCS changes (Table 6). Discussion 12 Months* P Value PCS TIPS LVP MCS TIPS LVP *Change compared with baseline. TIPS versus LVP change from baseline. Several uncontrolled studies have suggested that patients who undergo TIPS for refractory ascites experience improved quality of life Demonstrating a postprocedure improvement, however, is no substitute for a controlled comparison. Enrolling in a study, participating in Table 3. Univariate Predictors of PCS Randomization to TIPS 2.14 ( 1.82, 6.10).29 Requirement for LVP 4.22 ( 8.02, 0.42).03* Three or more LVP 5.41 ( 9.00, 1.81).005* More than 15 L cumulative ascites removed 5.68 ( 9.63, 1.73).007* Shortness of breath 3.68 ( 7.21, 0.15).05* Abdominal distention At 6-month visit 4.08 ( 4.16, 12.33).34 At 12-month visit 5.82 ( 10.41, 1.22).02* Abdominal pain 0.57 ( 4.18, 3.05).76 Confusion 4.16 ( 7.91, 0.41).03* Taking lactulose 0.40 ( 4.70, 3.90).86 Hospitalizations At 6-month visit 2.96 ( 1.36, 7.29).19 At 12-month visit 7.00 ( 11.99, 2.01).008* Emergency department visit 0.54 ( 2.99, 4.08).76 Diuretics (any vs. none) 1.56 ( 2.86, 5.98).49 Diuretics (dosage effect) 0.35 ( 1.39, 2.08).70 *P.05 is considered significant. Table 4. Predictors of PCS, Multivariate Analysis Baseline PCS 0.53 ( 0.72, 0.33).001* Randomization to TIPS 0.31 ( 3.74, 4.36).88 Three or more LVP 5.12 ( 9.14, 1.09).02* Confusion 4.10 ( 7.73, 0.47).03* Hospitalizations At 6 months 1.63 ( 2.97, 6.23).49 At 12 months 5.55 ( 10.10, 0.99).02* *P.05 is considered significant. quality of life surveys, undergoing closer medical scrutiny, and simply allowing for the passage of time may lead to improved perceptions of quality of life. 17 In contrast, we analyzed quality of life data from a randomized, controlled trial between continued medical therapy and performance of TIPS for refractory ascites. Within each randomization group, quality of life improved during follow-up. Although the difference in improvement between the groups was not statistically significant, there was a trend toward enhanced quality of life in MCS after TIPS. Baseline measurements of quality of life in our study population were comparable with those from previous studies. 6-8 For example, Arguedas et al. 7 found that in individuals with Child-Turcotte-Pugh class C cirrhosis, mean PCS and MCS were and results that closely match our data. To put these numbers in perspective, mean PCS and MCS in individuals with Child-Turcotte-Pugh class A cirrhosis, individuals with chronic obstructive pulmonary disease, and the general United States population are and 45 12, and 48 11, and and 50 10, respectively. 7,8 Therefore, the increases in PCS and MCS of 0.5 to 7 points demonstrated in our study should be considered a modest improvement. Randomization to TIPS as compared with repeated LVP was associated with greater improvement in the Table 5. Univariate Predictors of MCS Randomization to TIPS 4.59 ( 0.05, 9.23).06 Requirement for LVP 2.96 ( 7.82, 1.90).24 Three or more LVP 2.79 ( 7.45, 1.87).25 More than 15 L cumulative ascites removed 3.00 ( 8.05, 2.06).25 Shortness of breath 1.81 ( 6.53, 2.90).45 Abdominal distention 2.67 ( 2.32, 7.65).30 Abdominal pain 0.54 ( 3.76, 4.83).81 Confusion 1.99 ( 6.61, 2.63).40 Taking lactulose 0.39 ( 4.74, 5.52).88 Hospitalizations 0.18 ( 4.29, 3.94).93 Emergency department visit 0.55 ( 4.87, 3.77).80 Diuretics (any vs. none) 2.50 ( 7.79, 2.79).36 Diuretics (dosage effect) 0.60 ( 2.67, 1.47).57
5 HEPATOLOGY, Vol. 42, No. 3, 2005 CAMPBELL ET AL. 639 Table 6. Predictors of MCS, Multivariate Analysis Baseline MCS 0.57 ( 0.75, 0.40).001* Randomization to TIPS 5.29 (0.94, 9.64).02* Confusion At 6 months 1.39 ( 4.42, 7.20).64 At 12 months 8.06 ( 14.70, 1.43).02* *P.05 is considered significant. mental component scale of the SF-36 after adjusting for the development of confusion in some subjects. Patients who achieve ascites control after TIPS may believe they are in better health. They no longer experience repeated reaccumulation of ascites fluid and thus are not dependent on repeated LVP. Furthermore, some patients may have a better self-image and fit better into their usual clothes. They may also have improved appetite and breathing mechanics. Nutritional status and pleasure derived from eating may also increase. However, if encephalopathy develops, these possible benefits may be negated. If the development of hepatic encephalopathy after TIPS could be predicted accurately, then TIPS could be reserved for those patients who would experience a quality of life benefit. Randomization to TIPS was not directly associated with changes in the physical component scale. Instead, predictors of improvement in the physical component scale were: lack of severe ascites, confusion, and requirement for hospitalization. Logically, these three predictors of quality of life changes are likely affected by the performance of TIPS. Therefore, although TIPS has no direct impact on changes in PCS, it seems to cause changes in PCS indirectly through its effects on these three clinical variables. We identified severe ascites, confusion, and hospitalizations as the variables most associated with quality of life changes among patients with refractory ascites. Our findings are consistent with those of other investigators. 6-8 As part of our trial protocol, patients were selected to have relatively preserved model for end-stage liver disease scores. Therefore, we could not investigate how model for end-stage liver disease score influences quality of life in this population. Other variables that may influence quality of life changes include medications, muscle cramps, and pruritus. 6-9 Our database did not allow us to accurately assess changes in muscle cramps and pruritus between the two randomization groups. We did examine requirement for lactulose and found that confusion was more closely associated with quality of life changes. Diuretic dosage was not associated with changes in quality of life in our patient population. Our analysis could be criticized because only 51 patients completed quality of life assessment at 12-month follow-up, compared with a starting number of 106. Dropout was balanced between the TIPS and LVP groups and was due to the high rate of liver transplantation and death in this study population with decompensated cirrhosis. Ninety-seven percent of enrolled patients completed baseline surveys, and 90% of patients who did not undergo interval transplantation or death completed follow-up surveys. Furthermore, survey completion rates were similar between the two randomization groups. Because the study was a randomized, controlled trial, patients were similar with respect to baseline demographic and clinical variables. For patients with advanced liver disease, physicians and patients may have markedly different perceptions of quality of life. 15,18,19 Therefore, objective instruments are essential to evaluate any quality-of-life benefit from TIPS. The SF-36 is a general assessment of quality of life not specifically designed for the evaluation of patients with advanced liver disease. However, this tool has been widely used for the evaluation of decompensated cirrhosis. 6,7,15,16 Furthermore, its widespread use in the medical literature for the evaluation of other disease states makes our findings more easily accessible. In conclusion, patients with refractory ascites randomized to TIPS or continued medical management had similar changes in quality of life during 1 year of follow-up. Similar changes in quality of life between treatment arms were explained by competing effects of severe ascites, hospitalizations, and the development of confusion. TIPS did lead to improvement in the mental component scale, only after adjusting for the negative effects of confusion in some subjects. In the absence of the ability to predict how TIPS will affect the course of encephalopathy, ascites, and hospitalizations in the individual patient, the decision to perform TIPS cannot be justified based on expectations for improved quality of life. References 1. Sanyal AJ, Genning C, Reddy KR, Wong F, Kowdley KV, Benner K, et al. The North American study for the treatment of refractory ascites. Gastroenterology 2003;124: Lebrec D, Giuily N, Hadengue A, Vilgrain V, Moreau R, Poynard T, et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists. J Hepatol 1996; 25: Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Ruiz del Arbol L, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002;123: Rossle M, Ochs A, Gulberg V, Siegerstetter V, Holl J, Deibert P, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000;342: Salerno F, Merli Manuela M, Riggio O, Cazzaniga M, Valeriano V, Pozzi M, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. HEPATOLOGY 2004;40:
6 640 CAMPBELL ET AL. HEPATOLOGY, September Marchesini G, Bianchi G, Amodio P, Salerno F, Merli M, Panella C, et al. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology 2001;120: Arguedas MR, DeLawrence TG, McGuire MB. Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Dig Dis Sci 2003;48: Younossi ZM, Boparai N, Price LL, Kiwi ML, McCormick M, Guyatt G. Health-related quality of life in chronic liver disease: the impact of type and severity of liver disease. Am J Gastroenterol 2001;96: Cordoba J, Flavia M, Jacas C, Sauleda S, Esteban JI, Guardia J. Quality of life and cognitive function in hepatitis C at different stages of liver disease. J Hepatol 2003;39: Zhuang ZW, Ten GJ, Jeffery RF, Gemery JM, d Othee BJ, Bettmann MA. Long-term results and quality of life in patients treated with transjugular intrahepatic portosystemic shunts. AJR Am J Roentgenol 2002;179: Gulberg V, Liss I, Bilzer M, Waggershauser T, Reiser M, Gerbes AL. Improved quality of life in patients with refractory or recidivant ascites after insertion of transjugular intrahepatic portosystemic shunts. Digestion 2002;66: Nazarian GK, Ferral H, Bjarnason H, Castaneda-Zuniga WR, Rank JM, Bernadas CA, et al. Effect of transjugular intrahepatic portosystemic shunt on quality of life. AJR Am J Roenteneol 1996;167: Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. HEPATOLOGY 1996;23: Ware JE, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: a user s manual. Boston: The Health Institute, Younossi ZM, Boparai N, McCormick M, Price LL, Guyatt G. Assessment of utilities and health-related quality of life in patients with chroni liver disease. Am J Gastroenterol 2001;96: van der Plas SM, Hansen BE, de Boer JB, Stijnen T, Passchier J, de Man RA, et al. The liver disease symptom index 2.0; validation of a diseasespecific questionnaire. Qual Life Res 2004;13: Sprangers MA, Moinpour CM, Moynihan TJ, Patrick DL, Revicki DA. Clinical Significance Consensus Meeting Group. Assessing meaningful change in quality of life over time: a users guide for clinicians. Mayo Clinic Proceedings 2002;77: Chong CAKY, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, et al. Heath-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003;98: Wells CD, Murrill WB, Arguedas MR. Comparison of health-related quality of life preferences between physicians and cirrhotic patients: implications for cost-utility analyses in chronic liver disease. Dig Dis Sci 2004;49:
The Management of Ascites & Hepatorenal Syndrome. Florence Wong University of Toronto. Falk Symposium March 14, 2008
The Management of Ascites & Hepatorenal Syndrome Florence Wong University of Toronto Falk Symposium March 14, 2008 Management of Ascites Sodium Restriction Mandatory at all stages of ascites in order to
More informationManagement of Cirrhotic Complications Uncontrolled Ascites. Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University
Management of Cirrhotic Complications Uncontrolled Ascites Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University Topic Definition, pathogenesis Current therapeutic options Experimental treatments
More informationFactors Predicting Survival after Transjugular Intrahepatic Portosystemic Shunt Creation: 15 Years Experience from a Single Tertiary Medical Center
Factors Predicting Survival after Transjugular Intrahepatic Portosystemic Shunt Creation: 15 Years Experience from a Single Tertiary Medical Center Jen-Jung Pan, MD, PhD, Chaoru Chen, PhD, James G. Caridi,
More informationEDUCATION PRACTICE. Management of Refractory Ascites. Clinical Scenario. The Problem
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:1187 1191 EDUCATION PRACTICE Management of Refractory Ascites ANDRÉS CÁRDENAS and PERE GINÈS Liver Unit, Institute of Digestive Diseases, Hospital Clínic,
More informationManagement of Ascites and Hepatorenal Syndrome. Florence Wong University of Toronto. June 4, /16/ Gore & Associates: Consultancy
Management of Ascites and Hepatorenal Syndrome Florence Wong University of Toronto June 4, 2016 6/16/2016 1 Disclosures Gore & Associates: Consultancy Sequana Medical: Research Funding Mallinckrodt Pharmaceutical:
More informationInitial approach to ascites
Ascites: Filling and Draining the Water Balloon Common Pathogenesis in Refractory Ascites, Hyponatremia, and Cirrhosis intrahepatic resistance sinusoidal portal hypertension Splanchnic vasodilation (effective
More informationAscites Management. Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology
Ascites Management Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Disclosure 1. The speaker Atif Zaman, MD MPH have no relevant
More informationA COMPARISON OF PARACENTESIS AND TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNTING
A COMPARISON OF AND TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC ING IN PATIENTS WITH ASCITES MARTIN RÖSSLE, M.D., ANDREAS OCHS, M.D., VEIT GÜLBERG, M.D., VOLKER SIEGERSTETTER, M.D., JOSEPH HOLL, M.D., PETER
More informationVirtual Mentor American Medical Association Journal of Ethics December 2008, Volume 10, Number 12:
Virtual Mentor American Medical Association Journal of Ethics December 2008, Volume 10, Number 12: 805-809. CLINICAL PEARL Indications for Use of TIPS in Treating Portal Hypertension Elizabeth C. Verna,
More informationAscites is the most common complication of cirrhosis and. Natural History of Patients Hospitalized for Management of Cirrhotic Ascites
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:1385 1394 Natural History of Patients Hospitalized for Management of Cirrhotic Ascites RAMON PLANAS,* SILVIA MONTOLIU,* BELEN BALLESTÉ, MONICA RIVERA, MIREIA
More informationContraindications. Indications. Complications. Currently TIPS is considered second or third line therapy for:
Contraindications Absolute Relative Primary prevention variceal bleeding HCC if centrally located Active congestive heart failure Obstruction all hepatic veins Thomas D. Boyer, M.D. University of Arizona
More informationManagement of Cirrhosis Related Complications
Management of Cirrhosis Related Complications Ke-Qin Hu, MD, FAASLD Professor of Clinical Medicine Director of Hepatology University of California, Irvine Disclosure I have no disclosure related to this
More informationHepatorenal syndrome. Jan T. Kielstein Departent of Nephrology Medical School Hannover
Hepatorenal syndrome Jan T. Kielstein Departent of Nephrology Medical School Hannover Hepatorenal Syndrome 1) History of HRS 2) Pathophysiology of HRS 3) Definition of HRS 4) Clinical presentation of HRS
More informationNorepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome
Norepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome Disclosure I have no conflicts of interest to disclose Name: Margarita Taburyanskaya Title: PharmD, PGY1 Pharmacy Practice Resident
More informationFrom Sodium Retention to Therapy for Refractory Ascites The Role for New Drugs. Florence Wong University of Toronto. Falk Symposium October 14, 2007
From Sodium Retention to Therapy for Refractory Ascites The Role for New Drugs Florence Wong University of Toronto Falk Symposium October 14, 2007 Sodium Retention in Cirrhosis Occurs as a result of hemodynamic
More informationALEXANDER L. GERBES, 1 VEIT GÜLBERG, 1 TOBIAS WAGGERSHAUSER, 2 JOSEF HOLL, 1 AND MAXIMILIAN REISER 2
Renal Effects of Transjugular Intrahepatic Portosystemic Shunt in Cirrhosis: Comparison of Patients With Ascites, With Refractory Ascites, or Without Ascites ALEXANDER L. GERBES, 1 VEIT GÜLBERG, 1 TOBIAS
More informationImpact of Chronic Liver Disease and Cirrhosis on Health Utilities Using SF-6D and the Health Utility Index
LIVER TRANSPLANTATION 14:321-326, 2008 ORIGINAL ARTICLE Impact of Chronic Liver Disease and Cirrhosis on Health Utilities Using SF-6D and the Health Utility Index Amy A. Dan, 1,2 Jillian B. Kallman, 1,2
More informationACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis
ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis Guadalupe Garcia-Tsao, M.D., 1 Arun J. Sanyal, M.D., 2 Norman D. Grace,
More informationProf. Mohammad Umar. MBBS, MCPS, FCPS, FACG (USA), FRCP (London), FRCP (Glasgow), FAGA
Prof. Mohammad Umar MBBS, MCPS, FCPS, FACG (USA), FRCP (London), FRCP (Glasgow), FAGA Chairman and Head Department of Medicine Rawalpindi Medical College, Rawalpindi. Consultant Gastroenterologist / Hepatologist
More informationEDUCATION PRACTICE. Cirrhosis With Refractory Ascites: Serial Large Volume Paracentesis, TIPS, or Transplantation?
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:931 935 EDUCATION PRACTICE Cirrhosis With Refractory Ascites: Serial Large Volume Paracentesis, TIPS, or Transplantation? VANDANA KHUNGAR* and SAMMY SAAB*,
More informationHepatorenal syndrome a defined entity with a standard treatment?
Hepatorenal syndrome a defined entity with a standard treatment? Falk Symposium 162 Dresden - October 14, 2007 Alexander L. Gerbes Klinikum of the University of Munich Grosshadern Department of Medicine
More informationOrgan allocation for liver transplantation: Is MELD the answer? North American experience
Organ allocation for liver transplantation: Is MELD the answer? North American experience Douglas M. Heuman, MD Virginia Commonwealth University Richmond, VA, USA March 1998: US Department of Health and
More informationT herapeutic (that is, total) paracentesis is used in patients
90 LIVER AND BILIARY DISEASE Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by : a randomised pilot study R Moreau, T
More informationDOTTORATO DI RICERCA IN SCIENZE MEDICO-CHIRURGICHE GASTROENTEROLOGICHE E DEI TRAPIANTI TITOLO TESI FACTORS PREDICTING MORTALITY AFTER TIPS FOR
Alma Mater Studiorum Università di Bologna DOTTORATO DI RICERCA IN SCIENZE MEDICO-CHIRURGICHE GASTROENTEROLOGICHE E DEI TRAPIANTI Ciclo XXII Settore/i scientifico-disciplinare/i di afferenza: MED/12 TITOLO
More informationJOURNAL PRESENTATION. Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013
JOURNAL PRESENTATION Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013 THE COMBINATION OF OCTREOTIDE AND MIDODRINE IS NOT SUPERIOR TO ALBUMIN IN PREVENTING RECURRENCE OF ASCITES AFTER LARGE-VOLUME PARACENTESIS
More informationControversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate
Controversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate Patrick Northup, MD, FAASLD, FACG Medical Director, Liver Transplantation University of Virginia
More informationAASLD PRACTICE GUIDELINE. The Role of Transjugular Intrahepatic Portosystemic Shunt in the Management of Portal Hypertension. Preamble.
AASLD PRACTICE GUIDELINE The Role of Transjugular Intrahepatic Portosystemic Shunt in the Management of Portal Hypertension Thomas D. Boyer 1 and Ziv J. Haskal 2 Preamble The recommendations in this article
More informationMANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT
MANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT Sherona Bau, ACNP The Pfleger Liver Institute 200 UCLA Medical Plaza, Suite 214 Los Angeles, CA 90095 September 30, 2017 I
More informationDeterminants of quality of life in chronic liver patients
Alimentary Pharmacology & Therapeutics Determinants of quality of life in chronic liver patients J. J. GUTTELING*, R. A. DE MAN*, S. M. VAN DER PLAS*, S. W. SCHALM*, J. J. V. BUSSCHBACH & A.-S. E. DARLINGTON
More informationProlonged Follow-Up of Patients in the U.S. Multicenter Trial of Ursodeoxycholic Acid for Primary Biliary Cirrhosis
American Journal of Gastroenterology ISSN 0002-9270 C 2004 by Am. Coll. of Gastroenterology doi: 10.1111/j1572-0241.2004.04047.x Published by Blackwell Publishing Prolonged Follow-Up of Patients in the
More informationCIRRHOSIS Definition
Cirrhosis Update Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Gastroenterology & Hepatology Weill Cornell Medical College CIRRHOSIS Definition Irreversible fibrous
More informationIntravenous Furosemide and Human Albumin for Treatment of Cirrhotic Ascites: Useful or Harmful?
Ibnosina J Med BS 83 ARTICLE Intravenous Furosemide and Human Albumin for Treatment of Cirrhotic Ascites: Useful or Harmful? Faisal O. Abubakor, Hind I. Fallatah, Hisham O. Akbar Department of Medicine,
More informationFilippo Schepis, MD Università degli Studi di Modena e Reggio Emilia
Filippo Schepis, MD Università degli Studi di Modena e Reggio Emilia Il sottoscritto dichiara di non aver avuto/di aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione
More informationThe decision to perform combined kidney/liver
ORIGINAL ARTICLES Renal Function after Orthotopic Liver Transplantation is Predicted by Duration of Pretransplantation Creatinine Elevation Mical S. Campbell, 1 David S. Kotlyar, 2 Colleen M. Brensinger,
More informationManaging Cirrhosis. Cirrhosis of the liver is a progressive, fibrosing. Ascites. By Cameron Ghent, MD, FRCPC. Complications of Cirrhosis
Focus on CME at the University of Western Ontario Managing Cirrhosis By Cameron Ghent, MD, FRCPC Cirrhosis of the liver is a progressive, fibrosing process resulting in nodule formation and microvascular
More informationTreating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC
Treating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC mino.mitri@ubc.ca No Conflict of Interest 157 patients 157 patients 6 transplanted Criteria Liver
More informationAnaesthetic considerations and peri-operative risks in patients with liver disease
Anaesthetic considerations and peri-operative risks in patients with liver disease Dr. C. K. Pandey Professor & Head Department of Anaesthesiology & Critical Care Medicine Institute of Liver and Biliary
More informationHepatorenal syndrome. Jan Jan T. T. Kielstein Departent of of Nephrology Medical School School Hannover
Hepatorenal syndrome Jan Jan T. T. Kielstein Departent of of Nephrology Medical School School Hannover Hepatorenal Syndrome 1) History of HRS 2) Pathophysiology of HRS 3) Definition of HRS 4) Clinical
More informationEASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis
EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis European Association for the Study of the Liver 1 Ascites is the
More informationTerlipressin: An Asset for Hepatologists!
DIAGNOSTIC AND THERAPEUTIC ADVANCES IN HEPATOLOGY Terlipressin: An Asset for Hepatologists! S.K. Sarin and Praveen Sharma One Case Scenario A 48-year-old male with alcoholic cirrhosis who was abstinent
More informationReduced Quality of Life in Patients with Chronic Viral Liver Disease as Assessed by SF12 Questionnaire
Reduced Quality of Life in Patients with Chronic Viral Liver Disease as Assessed by SF12 Questionnaire Neda Svirtlih 1, Sladjana Pavic 2, Dragica Terzic 3, Dragan Delic 1, Jasmina Simonovic 1, Eleonora
More informationCauses of Liver Disease in US
Learning Objectives Updates in Outpatient Cirrhosis Management Jennifer Guy, MD MAS Director, Liver Cancer Program California Pacific Medical Center guyj@sutterhealth.org Review cirrhosis epidemiology,
More informationAre we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?
Rajani Sharma, PGY1 Geriatrics CRC Project, 12/19/13 Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? A. Study Purpose and Rationale Hepatocellular carcinoma
More informationThe MELD Score in Advanced Liver Disease: Association with Clinical Portal Hypertension and Mortality
The MELD Score in Advanced Liver Disease: Association with Clinical Portal Hypertension and Mortality Sammy Saab, 1,2 Carmen Landaverde, 3 Ayman B Ibrahim, 2 Francisco Durazo, 1,2 Steven Han, 1,2 Hasan
More informationEfficacy of tolvaptan in patients with refractory ascites in a clinical setting
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.4254/wjh.v7.i12.1685 World J Hepatol 2015 June 28; 7(12): 1685-1693 ISSN 1948-5182 (online)
More informationSteps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV
Overview of Liver Disease Associated With HCV Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco San Francisco,
More informationLong term administration of human albumin improves survival in patients with cirrhosis and refractory ascites
Received: 3 May 2018 Revised: 2 August 2018 Accepted: 12 September 2018 DOI: 10.1111/liv.13968 CIRRHOSIS AND LIVER FAILURE Long term administration of human albumin improves survival in patients with cirrhosis
More informationProgram Disclosure. This program is supported by an educational grant from Salix Pharmaceuticals.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship
More informationReview Article Management of Renal Failure and Ascites in Patients with Cirrhosis
SAGE-Hindawi Access to Research International Journal of Hepatology Volume 2011, Article ID 790232, 7 pages doi:10.4061/2011/790232 Review Article Management of Renal Failure and Ascites in Patients with
More informationCase Report Low-Dose Tolvaptan for the Treatment of Dilutional Hyponatremia in Cirrhosis: A Case Report and Literature Review
Case Reports in Hepatology, Article ID 795261, 4 pages http://dx.doi.org/10.1155/2014/795261 Case Report Low-Dose Tolvaptan for the Treatment of Dilutional Hyponatremia in Cirrhosis: A Case Report and
More informationPredictors of hepatorenal syndrome in alcoholic liver cirrhosis
Predictors of hepatorenal syndrome in alcoholic liver cirrhosis Martin Janicko, Eduard Veseliny, Gabriela Senajova, Peter Jarcuska Background. Alcoholic liver disease is a major cause of liver cirrhosis
More informationEvidence Analysis Library Research Project
Evidence Analysis Library Research Project EAL question: What is the evidence to support the use of supplementing BCAA in patients with cirrhosis to 1) prevent further liver damage or improve liver function;
More informationCirrhosis the end stage of chronic liver disease characterized
Suzanne E. Minor, MD, FAAFP; Irmanie Eliacin, MD; Sanaz Kashan, MD; Ebony B. Whisenant, MD Florida International University, Herbert Wertheim College of Medicine, Miami seminor@fiu.edu The authors reported
More informationCIRRHOTIC MANAGEMENT
DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They are intended to serve as a general statement regarding appropriate patient care
More informationManagement of ascites in cirrhosis
doi:10.1111/j.1440-1746.2011.06925.x ADVANCES IN CLINICAL PRACTICE jgh_6925 11..20 Management of ascites in cirrhosis Florence Wong Department of Medicine, Toronto General Hospital, University of Toronto,
More informationHepatorenal Syndrome
Necker Seminars in Nephrology Institut Pasteur Paris, April 22, 2013 Hepatorenal Syndrome Dr. Richard Moreau 1 INSERM U773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, 2 Université Paris Diderot
More informationManagement of refractory ascites in cirrhosis: Are we out of date?
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.4254/wjh.v8.i28.1182 World J Hepatol 2016 October 8; 8(28): 1182-1193 ISSN 1948-5182 (online)
More informationJMSCR Vol 05 Issue 11 Page November 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 71.58 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i11.33 Prevalence of Hyponatremia among patients
More informationESLD a Guide for HIV Physicians. Marion Peters University of California San Francisco June 2015
ESLD a Guide for HIV Physicians Marion Peters University of California San Francisco June 2015 Disclosures Honararia from Johnson and Johnson Roche Merck Gilead Spouse employee of Hoffman La Roche Natural
More informationEnd-Stage Liver Disease (ESLD): A Guide for HIV Physicians
Slide 1 of 32 End-Stage Liver Disease (ESLD): A Guide for HIV Physicians Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California
More informationTransjugular Intrahepatic Portosystemic Shunt for Acute Variceal Bleeding in Patients with Viral Liver Cirrhosis: Predictors of Early Mortality
Early Mortality with TIPS for Variceal Bleeding Interventional Radiology Original Research Transjugular Intrahepatic Portosystemic Shunt for Acute Variceal Bleeding in Patients with Viral Liver Cirrhosis:
More informationConflict of interest disclosures. Complications of end stage liver disease. None. The many complications of Cirrhosis. Portal Hypertension.
Complications of end stage liver disease Conflict of interest disclosures None Amir Qamar, MD Instructor of Medicine Brigham and Women s s Hospital Harvard Medical School Boston, MA 02115 The many complications
More informationManagement of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL
Management of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL Terminology Acute decompensation of cirrhosis - stable patient with sudden deterioration Acute-on-chronic liver failure
More informationOn February 27, 2002, the system of organ allocation
Persistent Ascites and Low Serum Sodium Identify Patients With Cirrhosis and Low MELD Scores Who Are at High Risk for Early Death Douglas M. Heuman, 1,3 Souheil G. Abou-assi, 1,3 Adil Habib, 1,3 Leslie
More informationEmricasan (IDN-6556) administered orally for 28 days lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension
Emricasan (IDN-6556) administered orally for 28 days lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension Guadalupe Garcia-Tsao, Michael Fuchs, Mitchell Shiffman,
More informationUpdate in abdominal Surgery in cirrhotic patients
Update in abdominal Surgery in cirrhotic patients Safi Dokmak HBP department and liver transplantation Beaujon Hospital, Clichy, France Cairo, 5 April 2016 Cirrhosis Prevalence in France (1%)* Patients
More informationArticle. Management of Decompensate Cirrhotic Patients Awaiting Liver Transplantation and Early Post-transplant Care INTRODUCTION.
THAI J 124 GASTROENTEROL and Early Post-transplant InvitedCare Management of Decompensate Cirrhotic Patients Awaiting Liver Transplantation and Early Post-transplant Care Article Sobhonslidsuk A INTRODUCTION
More informationMichele Bettinelli RN CCRN Lahey Health and Medical Center
Michele Bettinelli RN CCRN Lahey Health and Medical Center Differentiate the types of varices Identify glue preparations utilized when treating gastric varices Review the process of glue administration
More informationTreatment of Overt Hepatic Encephalopathy: Focus on Outpatient Management
Treatment of Overt Hepatic Encephalopathy: Focus on Outpatient Management Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation
More informationFactors associated with waiting time on the liver transplant list: an analysis of the United Network for Organ Sharing (UNOS) database
ORIGINAL ARTICLE Annals of Gastroenterology (2018) 31, 1-6 Factors associated with waiting time on the liver transplant list: an analysis of the United Network for Organ Sharing (UNOS) database Judy A.
More informationBarbara Rus Gadžijev Peter Popovič Klinični inštitut za radiologijo UKC Ljubljana
STROKOVNI SESTANEK ZDRUŽENJA HEMATOLOGOV SLOVENIJE IN ZDRUŽENJA ZA TRANSFUZIJSKO MEDICINO, Terme Zreče, 17.-18.4.2015 Barbara Rus Gadžijev Peter Popovič Klinični inštitut za radiologijo UKC Ljubljana goals,
More informationTherapy Insight: management of hepatorenal syndrome
Therapy Insight: management of hepatorenal syndrome Andrés Cárdenas and Pere Ginès* SUMMARY Hepatorenal syndrome (HRS), a feared complication of advanced cirrhosis, is characterized by functional renal
More informationPAPER. Role, Indications, and Utility in the Era of Liver Transplantation
Distal Splenorenal Shunt PAPER Role, Indications, and Utility in the Era of Liver Transplantation Roger L. Jenkins, MD; Roberto Gedaly, MD; James J. Pomposelli, MD, PhD; Elizabeth A. Pomfret, MD, PhD;
More informationHyeon Jeong Goong, Sang Gyune Kim, Seung Sik Park, Youn Hee Cho, Young Seok Kim, Boo Sung Kim
Soonchunhyang Medical Science 18(1):56-60, June 2012 pissn: 2233-4289 I eissn: 2233-4297 CASE REPORT Complete Remission of Refractory Hepatic Hydrothorax in Patient with Advanced Liver Cirrhosis and Hepatocellular
More informationThe Leeds Teaching Hospitals NHS Trust Transjugular Intrahepatic Portosystemic Shunt (TIPS)
n The Leeds Teaching Hospitals NHS Trust Transjugular Intrahepatic Portosystemic Shunt (TIPS) Information for patients Your liver doctor has recommended that you have a Transjugular Intrahepatic Portosystemic
More informationB C Outlines. Child-Pugh scores
B C 2016-12-09 Outlines Child-Pugh scores CT MRI Fibroscan / ARFI Histologic Scoring Systems for Fibrosis Fibrosis METAVIR Ishak None 0 0 Portal fibrosis (some) 1 1 Portal fibrosis (most) 1 2 Bridging
More informationManagement of the Cirrhotic Patient in the ICU
Management of the Cirrhotic Patient in the ICU Peter E. Morris, MD Professor & Chief, Pulmonary, Critical Care and Sleep Medicine University of Kentucky Conflict of Interest Funding US National Institutes
More informationCare of the Patient With Cirrhosis
REVIEW Care of the Patient With Cirrhosis Anitha Yadav, M.D., and Hugo E. Vargas, M.D. Caring for patients with cirrhosis involves multidisciplinary and timely management of several complications while
More informationAn assessment of different scoring systems in cirrhotic patients undergoing nontransplant surgery
The American Journal of Surgery (2012) 203, 589 593 North Pacific Surgical Association An assessment of different scoring systems in cirrhotic patients undergoing nontransplant surgery Marlin Wayne Causey,
More information100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days
100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days TheraSphere [US package insert]. Surrey, UK: Biocompatibles UK Ltd,
More informationMedicine. Differential Clinical Impact of Ascites in Cirrhosis and Idiopathic Portal Hypertension
Medicine OBSERVATIONAL STUDY Differential Clinical Impact of Ascites in Cirrhosis and Idiopathic Portal Hypertension Hitoshi Maruyama, MD, PhD, Takayuki Kondo, MD, PhD, Tadashi Sekimoto, MD, PhD, and Osamu
More informationThe Association Between the Serum Sodium Level and the Severity of Complications in Liver Cirrhosis
ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.2.106 The Association Between the Serum Sodium Level and the Severity of Complications in Liver Cirrhosis Jong Hoon Kim, June Sung Lee, Seuk Hyun Lee, Won Ki
More informationThe role of TIPS in the management of liver transplant candidates
Original Article The role of TIPS in the management of liver transplant candidates United European Gastroenterology Journal 217, Vol. 5(8) 11 117! Author(s) 217 Reprints and permissions: sagepub.co.uk/journalspermissions.nav
More informationTIPS for Refractory Ascites: A 6-Year Single-Center Experience With Expanded Polytetrafluoroethylene Covered Stent-Grafts
Vascular and Interventional Radiology Original Research Bercu et al. TIPS for Refractory Ascites Vascular and Interventional Radiology Original Research Zachary L. Bercu 1 Aaron M. Fischman 1 Edward Kim
More informationDiagnosis and therapy of ascites in liver cirrhosis
Online Submissions: http://www.wjgnet.com/1007-9327office wjg@wjgnet.com doi:10.3748/wjg.v17.i10.1237 World J Gastroenterol 2011 March 14; 17(10): 1237-1248 ISSN 1007-9327 (print) ISSN 2219-2840 (online)
More informationTransjugular Intrahepatic Portosystemic Shunt (TIPS) About your procedure
Patient Education Transjugular Intrahepatic Portosystemic Shunt (TIPS) About your procedure This handout explains what a transjugular intrahepatic portosystemic shunt is and what to expect when you have
More informationTransjugular Intrahepatic Portosystemic Shunts and Liver Transplantation in Patients With Refractory Hepatic Hydrothorax
Transjugular Intrahepatic Portosystemic Shunts and Liver Transplantation in Patients With Refractory Hepatic Hydrothorax Mark A. Jeffries,* Sahira Kazanjian, Mark Wilson, Jeffrey Punch, and Robert J. Fontana*
More informationUse of transjugular intrahepatic portosystemic shunt in liver disease
Vol. XVIII No. 3 JOURNAL OF VASCULAR NURSING PAGE 83 Use of transjugular intrahepatic portosystemic shunt in liver disease Patricia Ann Radovich, RN, MSN, CCRN, FCCM Persons with cirrhosis have many complications.
More informationChronic liver failure affects multiple organ systems and
ORIGINAL ARTICLES Model for End-Stage Liver Disease (MELD) Predicts Nontransplant Surgical Mortality in Patients With Cirrhosis Patrick G. Northup, MD,* Ryan C. Wanamaker, MD, Vanessa D. Lee, MD, Reid
More informationDRAFT. Angiography: Transjugular Intrahepatic Portosystemic Shunt (TIPS) What to expect. What is a transjugular intrahepatic portosystemic shunt?
UW MEDICINE PATIENT EDUCATION Angiography: Transjugular Intrahepatic Portosystemic Shunt (TIPS) What to expect This handout explains a transjugular intrahepatic portosystemic shunt and what to expect when
More informationCirrhotic Patients Are at Risk for Health Care Associated Bacterial Infections
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:979 985 Cirrhotic Patients Are at Risk for Health Care Associated Bacterial Infections MANUELA MERLI,* CRISTINA LUCIDI,* VALERIO GIANNELLI,* MICHELA GIUSTO,*
More informationManagement of Cirrhosis and Ascites
The new england journal of medicine review article current concepts Management of Cirrhosis and Ascites Pere Ginès, M.D., Andrés Cárdenas, M.D., Vicente Arroyo, M.D., and Juan Rodés, M.D. From the Liver
More informationIntron A Hepatitis C. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.05 Subject: Intron A Hepatitis C Page: 1 of 5 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationPALLIATIVE CARE IN END-STAGE LIVER DISEASE
PALLIATIVE CARE IN END-STAGE LIVER DISEASE Ken S. Ota, DO Family Medicine Banner Good Samaritan Medical Center Learning Objectives: Describe the common bio-psycho-social issues in end-stage liver disease
More informationHCV TREATMENT PRE- AND POST TRANSPLANTATION
HCV TREATMENT PRE- AND POST TRANSPLANTATION Mitchell L. Shiffman, MD, FACG Medical Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA IVer Liver Institute
More informationREVIEW. Ariel W. Aday, M.D.,* Nicole E. Rich, M.D.,* Arjmand R. Mufti, M.D., and Shannan R. Tujios, M.D.
REVIEW CON ( The Window Is Closed ): In Patients With Cirrhosis With Ascites, the Clinical Risks of Nonselective beta-blocker Outweigh the Benefits and Should NOT Be Prescribed Ariel W. Aday, M.D.,* Nicole
More informationAcute kidney injury and hepatorenal syndrome in cirrhosis
bs_bs_banner doi:10.1111/jgh.12709 REVIEW ARTICLE Acute kidney injury and hepatorenal syndrome in cirrhosis Mads Egerod Israelsen,* Lise Lotte Gluud and Aleksander Krag* *Department of Gastroenterology,
More informationRenal dysfunction is a common complication of
GASTROENTEROLOGY 2013;145:1280 1288 New Consensus Definition of Acute Kidney Injury Accurately Predicts 30-Day Mortality in Patients With Cirrhosis and Infection FLORENCE WONG, 1 JACQUELINE G. O LEARY,
More informationREFRACTORY ascites is the complication of portal
1192 THE NEW ENGLAND JOURNAL OF MEDICINE May 4, 199 THE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC STENT SHUNT FOR REFRACTORY ASCITES ANDREAS OCHS, M.D., MARTIN RÖSSLE, M.D., KLAUS HAAG, M.D., KARL-HEINZ
More information